Skip to main content
SpringerLink
Log in

Development of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

  • Chapter
Non-Myeloablative Allogeneic Transplantation

Part of the book series: Cancer Treatment and Research ((CTAR,volume 110))

Abstract

The field of BMT has entered a new phase based on insights into basic molecular and cellular biology. The mechanism of cure mediated by allogeneic HSCT is now believed to be at least partially mediated by cellular attack against tumor-associated antigens. Better understanding of these cellular targets and the means of targeting them specifically will allow a more precise application of cellular therapy than is currently possible. This in turn may make it possible to design therapies that are increasingly selective without the collateral toxicities of GVHD, infection, and direct organ damage that currently are the limiting features of allogeneic HSCT as racticed until recently. However, it remains a challenge to demonstrate that disease-control using reduced intensity preparative regimens is at least comparable to that achieved by traditional myeloablative HSCT. This will require carefully controlled studies in each the major diseases that have shown sensitivity to the immune-mediated effects of HSCT. The chapters below will highlight progress towards the goals of elucidating the role of NST.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. Osgood EE, Riddle MC, Mathews TJ. Aplastic anemia treated with daily transfusions and intravenous marrow: case report. Ann Intern Med 1939;13(357–367).

    Google Scholar 

  2. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001;411:385–9.

    Article  PubMed  CAS  Google Scholar 

  3. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989;320(4):197–204.

    Article  PubMed  CAS  Google Scholar 

  4. McGlave PB, Shu XO, Wen W, Anasetti C, Nademanee A, Champlin R, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years’ experience of the National Marrow Donor Program. Blood 2000;95(7):2219–25.

    PubMed  CAS  Google Scholar 

  5. Jacobson LO, E.L. S, Marks EK, Eldredge JH. Recovery from radiation injury. Science 1951;113:510–1.

    Article  PubMed  CAS  Google Scholar 

  6. Lorenz E, Uphoff EL, Reid TR, Shelton F. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J.Natl Cancer Inst 1961;12:197–201.

    Google Scholar 

  7. Uphoff DE. Genetic factors influencing irradiation protection by bone marrrow. I: the FI hybrid effect. J Natl Cancer Inst 1957;19:123–5.

    PubMed  CAS  Google Scholar 

  8. Snell GD. The Nobel Lectures in Immunology. Lecture for the Nobel Prize for Physiology or Medicine, 1980: Studies in histocompatibility. Scand J Immunol 1992;36(4):513–26.

    PubMed  CAS  Google Scholar 

  9. Barnes DWH, Corp JH, Loutitj F. Treatment of murine leukemia with x-rays an homologous bone marrow. Preliminary communication. Brit Med J 1956;2:626–7.

    Article  PubMed  CAS  Google Scholar 

  10. Bortin MM, Rimm AA, Saltzstein EC, Rodey GE. Graft vs leukemia III; apparent independent antihost and anti-leukemic activity of transplanted immunocompetent cells. Transplant 1973;16:182–8.

    Article  CAS  Google Scholar 

  11. Truitt RL, Johnson BD, McCabe CM, Weiler MB. Graft vs leukemia. In: Perraraj LM, Deeg,H.J. and Burakoff,S.J., editor. Graft vs. host disease. New York: Marcel Dekker; 1997. p. 385–423.

    Google Scholar 

  12. Good RA, Dalmasso AP, Martinez C, Archer OK, Pierre JC, Papermaster BW. The role of thymus in development of immunologic capacity in rabbits and mice. J Exp Med 1962;116:773–96.

    Article  PubMed  CAS  Google Scholar 

  13. Miller JE. Immunity and the thymus. Lancet 1963;1:43–5.

    Google Scholar 

  14. Cooper MD, Percy DY, Peterson RDA, Gabrielsen AF, Good RA. The two component concept of the lymphoid system. In: Bergsman O, Good,R.A., editor. Immunologic deficiency disease in man. Philadelphia: Lea & Febiger; 1968. p. 175–97.

    Google Scholar 

  15. Boak JL, Fox M, Wilson RE. Activity of lymphoid tissues from anti-lymphocyte serum treated mice. Lancet 1967;1:751–2.

    Google Scholar 

  16. Brent L, CourtenayT, G. G. Immunological reactivity of Lymphoid cells after treatment with anti—lymphocytic serum. Nature 1967;215:1461–4.

    Article  PubMed  CAS  Google Scholar 

  17. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol 1979;27:51–177.

    Article  PubMed  CAS  Google Scholar 

  18. Suthanthiran M. Transplantation tolerance: fooling mother nature. Proc Natl Acad Sci U S A 1996;93(22):12072–5.

    Article  PubMed  CAS  Google Scholar 

  19. Steinmuller I, Motulsky AG. Treatment of hereditary spherocytosis in peromyscus by radiation and allogeneic bone marrow transplantation. Blood 1967;29:320–30.

    PubMed  CAS  Google Scholar 

  20. Walker DG. Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science 1975;190 (4216):784–5.

    Article  PubMed  CAS  Google Scholar 

  21. Thomas ED. The development of the scientific foundation of hematopoietic cell transplantation based on anmal and human studies. In: Thomas EE, Blume KG, Forman SJ, editors. Hematopoietic Cell Transplantation. Malden, MA: Blackwell Scientific; 1999.

    Google Scholar 

  22. Matsnick JA, Lochte HL, Jr, Ashely CA, Thomas ED, Ferrebee JW. Autografts of bone marrow in dogs after letal total body radiation. Blood 1960;15:255–66.

    Google Scholar 

  23. Cavins JA, Scheer SC, Thomas ED, Ferrebee JW. The recovery of lethally irradiated dogs given infusions of autologous leukocytes preserved at -80°C. Blood 1964;23:38–43.

    PubMed  CAS  Google Scholar 

  24. Thomas ED, LeBlond R, Graham T, Storb R. Marrow infusions in dogs given midlethal or lethal irradiation. Radiat Res 1970;41 (1):113–24.

    Article  PubMed  CAS  Google Scholar 

  25. Storb R, Dreg HJ. Failure of allogeneic canine marrow grafts after total body irradiation: allogeneic “resistance” vs. transfusion induced sensitization. Transplantation 1986;42:571–80.

    Article  PubMed  CAS  Google Scholar 

  26. Storb R, Raff RF, Appelbaum FR, Graham TC, Schuening FG, Sale G, et al. Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts. Blood 1989;74(3):1139–43.

    PubMed  CAS  Google Scholar 

  27. Epstein RB, Storb R, Clift RA, Thomas ED. Autologous bone marrow grafts in dogs treated with lethal doses of cyclophosphamide. Cancer Res 1969;29(5):1072–5.

    PubMed  CAS  Google Scholar 

  28. Storb R, Epstein RB, Rudolph RH, Thomas ED. Allogeneic canine bone marrow transplantation following cyclophosphamide. Transplantation 1969;7(5):378–86.

    Article  PubMed  CAS  Google Scholar 

  29. Storb R, Weiden PL, Graham TC, Lerner KG, Nelson N, Thomas ED. Hemopoietic grafts between DLA-identical canine littermates following dimethyl myleran. Evidence for resistance to grafts not associated with DLA and abrogated by antithymocyte serum. Transplantation 1977;24(5):349–57.

    Article  PubMed  CAS  Google Scholar 

  30. van Beckkum DW, Balner H, Dicke KA. Experimental aspects of bone marrow transplantation in primates. Transplant Proc 1969; 1:25–30.

    Google Scholar 

  31. Thomas ED, Ferrebee JW. Irradiation and marrow transplantation studies in Cooperstown. Lancet 1960;11:1289–90.

    Article  Google Scholar 

  32. Dausset J. Leuco-agglutinins. IN Leucoagglutinins and blood transfusion. Vox Sang 1954;4:190.

    Google Scholar 

  33. Miescher P, Fauconnet M. Mise en evidence de differents groupes leucocytaires chez l’homme. Schweiz Med Wochenschr 1954;84: 597–9.

    Google Scholar 

  34. Dausset J. Leuco-agglutinins. IV Leuco-agglutinins and blood transfusion. Vox Sang 1954;4:190.

    Google Scholar 

  35. Payne R, Tripp M, Weigle J, Bodmer W, Bodmer J. A new leukocyte isoantigenic system in man. Cold Spring Harbor Symp Quant Biol 1964;29(285-).

    Article  PubMed  CAS  Google Scholar 

  36. Geraghty DE. Structure of the HLA class I region and expression of its resident genes. Curr Opin Immunol 1993;5(1):3–7.

    Article  PubMed  CAS  Google Scholar 

  37. Geraghty DE, Wei XH, Orr HT, Koller BH. Human leukocyte antigen F (HLA-F). An expressed HLA gene composed of a class I coding sequence linked to a novel transcribed repetitive element. J Exp Med 1990;171(1):1–18.

    Article  PubMed  CAS  Google Scholar 

  38. Geraghty DE, Koller BH, Orr HT. A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. Proc Natl Acad Sci U S A 1987;84(24):9145–9.

    Article  PubMed  CAS  Google Scholar 

  39. Koller BH, Geraghty DE, Shimizu Y, DeMars R, Orr HT. HLA-E. A novel HLA class I gene expressed in resting T lymphocytes. J Immunol 1988;141(3):897–904.

    PubMed  CAS  Google Scholar 

  40. Busch R, Mellins ED. Developing and shedding inhibitions: how MHC class II molecules reach maturity. Curr Opin Immunol 1996;8 (1):51–8.

    Article  PubMed  CAS  Google Scholar 

  41. Marsh SG, Bodmer JG. HLA class II region nucleotide sequences, 1995. Tissue Antigens 1995;46(3 (Pt 2)):258–80.

    Article  PubMed  CAS  Google Scholar 

  42. Rosner G, Martell J, Trucco M. Histocompatibility. IN Hematopoietic Stem Cell Therapy, Ball ED, Lister J, Law P, eds. W.B. Saunders Publishing Company, Philadelphia, PA, 2000.

    Google Scholar 

  43. Arnett KL, Moses JH, Williams F, Marsh SG, Bodmer JG, Parham P, et al. HLA-A *2607: sequence of a novel A*26 subtype predicted by DNA typing which shares the MA2.1 epitope with A*02, B*57 and B*58. Tissue Antigens 1996;47(5):422–5.

    Article  PubMed  CAS  Google Scholar 

  44. Begovich AB, McClure GR, Suraj VC, Helmuth RC, Fildes N, Bugawan TL, et al. Polymorphism, recombination, and linkage disequilibrium within the HLA class II region. J Immunol 1992;148(1):24958.

    Google Scholar 

  45. Sutherland DR, Keating A. The CD34 antigen: structure, biology, and potential clinical applications. J Hematother 1992;1(2):115–29.

    Article  PubMed  CAS  Google Scholar 

  46. Goodell MA, Rosenzweig M, Kim H, Marks DF, DeMaria M, Paradis G, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997;3(12):1337–45.

    Article  PubMed  CAS  Google Scholar 

  47. Nakauchi H. Hematopoietic stem cells: are they CD34positive or CD34-negative Nat Med 1998;4(9):1009–10.

    Article  PubMed  CAS  Google Scholar 

  48. Ema H, Takano H, Sudo K, Nakauchi H. In vitro self-renewal division of hematopoietic stem cells. J Exp Med 2000;192(9):12818.

    Article  Google Scholar 

  49. Gao Z, Fackler MJ, Leung W, Lumkul R, Ramirez M, Theobald N, et al. Human CD34+ cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34- cell preparations. Exper. Hematology 2000;29(7):910–21.

    Google Scholar 

  50. Storb R, Epstein RB, Ragde H, Bryant J, Thomas ED. Marrow engraftment by allogeneic leukocytes in lethally irradiated dogs. Blood 1967;30(6):805–11.

    PubMed  CAS  Google Scholar 

  51. Korbling M, Fliedner TM, Calvo W, Ross WM, Nothdurft W, Steinbach I. Albumin density gradient purification of canine hemopoietic blood stem cells (HBSC): long-term allogeneic engraftment without GVHreaction. Exp Hematol 1979;7(6):277–88.

    PubMed  CAS  Google Scholar 

  52. Gerhartz HH, Nothdurft W, Carbonell F, Fliedner TM. Allogeneic transplantation of blood stem cells concentrated by density gradients. Exp Hematol 1985;13(2):136–42.

    PubMed  CAS  Google Scholar 

  53. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988;1(8596):1194–8.

    Article  PubMed  CAS  Google Scholar 

  54. Siena S, Bregni M, Brando B, Ravagnani F, Bonadonna G, Gianni AM. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989;74(6):1905–14.

    PubMed  CAS  Google Scholar 

  55. Lazarus HM, Haynesworth SE, Gerson SL, Caplan AI. Human bone marrow-derived mesenchymal (stromal) progenitor cells (MPCs) cannot be recovered from peripheral blood progenitor cell collections. J Hematother 1997;6(5):447–55.

    PubMed  CAS  Google Scholar 

  56. Galotto M, Berisso G, Delfino L, Podesta M, Ottaggio L, Dallorso S, et al. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol 1999;27(9):1460–6.

    Article  PubMed  CAS  Google Scholar 

  57. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344(3):175–81.

    Article  PubMed  CAS  Google Scholar 

  58. Bensinger WI, Martin P, Clift Rea. A prospective, randomised trial of peripheral blood stem cells (PBSC) or marrow (BM) for patients undergoing allogeneic transplantation for hematologic malignancies. Blood 1999;94(suppl 1):3682.

    Google Scholar 

  59. Korbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995;85(6):1659–65.

    PubMed  CAS  Google Scholar 

  60. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Loffler H, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995;85(6):1666–72.

    PubMed  CAS  Google Scholar 

  61. Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM, Turner SA, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997;90(8):2939–51.

    PubMed  CAS  Google Scholar 

  62. Molineux G, McCrea C, Yan XQ, Kerzic P, McNiece I. Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with longterm repopulating potential. Blood 1997;89(11):3998–4004.

    PubMed  CAS  Google Scholar 

  63. Sudo Y, Shimazaki C, Ashihara E, Kikuta T, Hirai H, Sumikuma T, et al. Synergistic effect of FLT-3 ligand on the granulocyte colony-stimulating factor-induced mobilization of hematopoietic stem cells and progenitor cells into blood in mice. Blood 1997;89(9):3186–91.

    PubMed  CAS  Google Scholar 

  64. Buckner CD, Clift RA, Sanders JE, Stewart P, Bensinger WI, Doney KC, et al. Marrow harvesting from normal donors. Blood 1984;64(3):630–4.

    PubMed  CAS  Google Scholar 

  65. Confer DL, Stroncek DF. Bone marrow and peripheral blood stem cell donors. IN: Thomas ED BK, Forman SJ., Eds. In Bone Marrow Transplantation. Oxford: Blackwell Science; 1999.

    Google Scholar 

  66. Falanga A, Marchetti M, Evangelista V, Manarini S, Oldani E, Giovanelli S, et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 1999;93(8):2506–14.

    PubMed  CAS  Google Scholar 

  67. Becker PS, Wagle M, Matous S, Swanson RS, Pihan G, Lowry PA, et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997;3(1):45–9.

    PubMed  CAS  Google Scholar 

  68. Anderlini P, Przepiorka D, Seong D.Clinical toxicity and laboratory effects of granulocyte colony stimulating factor (filgrastim) mobilization and collection of peripheral blood progenitor cells in normal volunteers. 1995 (86): 4437–4445.

    Google Scholar 

  69. Ringden O, Remberger M, Runde V, Bornhauser M, Blau IW, Basara N, et al. Faster engraftment of neutrophils and platelets with peripheral blood stem cells from unrelated donors: a comparison with marrow transplantation. Bone Marrow Transplant 2000;26 Suppl 2:S6–8.

    Article  Google Scholar 

  70. Heldal D, Tjonnfjord G, Brinch L, Albrechtsen D, Egeland T, Steen R, et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 2000;25:1129–36.

    Article  PubMed  CAS  Google Scholar 

  71. Bacigalupo A, Zikos P, Van Lint MT, Valbonesi M, Lamparelli T, Gualandi F, et al. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: a single-center experience. Exp Hematol 1998;26(5):409–14.

    PubMed  CAS  Google Scholar 

  72. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996;88(7):2775–9.

    PubMed  CAS  Google Scholar 

  73. Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001;97(1):3380–9.

    Article  PubMed  CAS  Google Scholar 

  74. Majolino J, Saglio G, Scrime R. High incidence of chronic GvHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematological malignancies. Bone Marrow Transplant 1996;17:555–60.

    PubMed  CAS  Google Scholar 

  75. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000;95(12):3702–9.

    PubMed  CAS  Google Scholar 

  76. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304(25):1529–33.

    Article  PubMed  CAS  Google Scholar 

  77. Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Bregante S, et al. Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse. Haematologica 1998;83(10):896–903.

    PubMed  CAS  Google Scholar 

  78. Rocha V, Wagner JE, Jr., Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engi J Med 2000;342(25):1846–54.

    Article  CAS  Google Scholar 

  79. Thomson BG, Robertson KA, Gowan D, Heilman D, Broxmeyer HE, Emanuel D, et al. Analysis of engraftment, graft-versus-ho ’ disease, and immune recovery following unrelated donor cord b’ transplantation. Blood 2000;96(8):2703–11.

    PubMed  CAS  Google Scholar 

  80. Wagner JE. Umbilical cord blood transplantation: overview of the clinical experience. Blood Cells 1994;20(2–3):227–33.

    PubMed  CAS  Google Scholar 

  81. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001;344(24):1815–22.

    Article  PubMed  CAS  Google Scholar 

  82. Storb R, Epstein RB, Graham TC, Thomas ED. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970;9(3):240–6.

    Article  PubMed  CAS  Google Scholar 

  83. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976;6(4):468–75.

    Article  PubMed  CAS  Google Scholar 

  84. Powles RL, Barrett AJ, Clink H, Kay HE, Sloane J, McElwain TJ. Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet 1978;2(8104–5):1327–31.

    Article  PubMed  CAS  Google Scholar 

  85. Deeg HJ, Storb R, Weiden PL, Raff RF, Sale GE, Atkinson K, et al. Cyclosporin A and methotrexate in canine marrow transplantation: engraftment, graft-versus-host disease, and induction of intolerance. Transplantation 1982;34(1):30–5.

    Article  PubMed  CAS  Google Scholar 

  86. Deeg HJ, Storb R, Appelbaum FR, Kennedy MS, Graham TC, Thomas ED. Combined immunosuppression with cyclosporine and methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates. Transplantation 1984;37(1):62–5.

    Article  PubMed  CAS  Google Scholar 

  87. Nash RA, Antin JH, Karanes C, Fay JW, Avaalos BR, Yeager AM, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosponrine for prophylaxis of actue graft vs. host disease after marrow transplantation from unrelated donors. Blood 2000;96(6):2062–8.

    PubMed  CAS  Google Scholar 

  88. Yu C, Linsley P, Seidel K, Sale G, Deeg HJ, Nash RA, et al. Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-nonidentical marrow transplant model. Transplantation 2000;69(3):450–4.

    Article  PubMed  CAS  Google Scholar 

  89. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999;340(22):1704–14.

    Article  PubMed  CAS  Google Scholar 

  90. Owen RD. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945;102:400.

    Article  PubMed  CAS  Google Scholar 

  91. Burnet FJ, Fenner F. The production of antibodies. Melbourne: MacMillan; 1949.

    Google Scholar 

  92. Billingham RE, Brent L, Medawar PB. Actively acquiredtolerance of foreign cells. Nature 1953;172:603.

    Google Scholar 

  93. Wengler GS, Lanfranchi A, Frusca T, Verardi R, Neva A, Brugnoni D, et al. In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI). Lancet 1996;348(9040):1484–7.

    Article  PubMed  Google Scholar 

  94. Tsoi MS, Storb R, Weiden PL, Graham TC, Schroeder ML, Thomas ED. Canine marrow transplantation: are serum blocking factors necessary to maintain the stable chimeric state J Immunol 1975;114(2 Pt 1): 531–9.

    PubMed  Google Scholar 

  95. Atkinson K, Storb R, Weiden PL, Deeg HJ, Gerhard-Miller L, Thomas ED. In vitro tests correlating with presence or absence of graftvs-host disease in DLA nonidentical canine radiation chimeras: evidence that clonal abortion maintains stable graft-host tolerance. J Immunol 1980; 124(4):1808–14.

    PubMed  Google Scholar 

  96. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991–1045.

    Article  PubMed  CAS  Google Scholar 

  97. Mondino A, Khoruts A, Jenkins MK. The anatomy of T-cell activation and tolerance. Proc Natl Acad Sci U S A 1996;93(6):2245–52.

    Article  PubMed  Google Scholar 

  98. Schwartz RH. Models of T cell anergy: is there a common molecular mechanism? J Exp Med 1996;184(1):1–8.

    Article  PubMed  CAS  Google Scholar 

  99. Wells AD, Li XC, Li Y, Walsh MC, Zheng XX, Wu Z, et l. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999;5(11):1303–7.

    Article  PubMed  CAS  Google Scholar 

  100. Castro JE, Listman JA, Jacobson BA, Wang Y, Lopez PA, Ju S, et al. Fas modulation of apoptosis during negative selection of thymocytes. Immunity 1996;5(6):617–27.

    Article  PubMed  CAS  Google Scholar 

  101. TA. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997;99(3):396–402.

    Article  PubMed  CAS  Google Scholar 

  102. Zeng D, Lewis D, Dejbakhsh-Jones S, Lan F, Garcia-Ojeda M, Sibley R, et al. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999;189 (7):1073–81.

    Article  PubMed  Google Scholar 

  103. Krenger W, Cooke KR, Crawford JM, Sonis ST, Simmons R, Pan L, et al. Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease. Transplantation 1996;62(9):1278–85.

    Article  PubMed  CAS  Google Scholar 

  104. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997;89(8):304–854.

    Google Scholar 

  105. Storb R, Yu C, Barnett T, Wagner JL, Deeg HJ, Nash RA, et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 1999;94(3):1131–6.

    PubMed  CAS  Google Scholar 

  106. Wekerle T, Sykes M. Mixed chimerism as an approach for the induction of transplantation tolerance. Transplantation 1999;68(4):45967.

    Article  Google Scholar 

  107. Sykes M, Preffer F, McAfee S, Saidman SL, Weymouth D, Andrews DM, et al. Mixed lymphohaemopoietic chimerism and graftversus-lymphoma effects after non-myeloablative therapy and HLAmismatched bone-marrow transplantation. Lancet 1999;353(9166):1755–9.

    Article  PubMed  CAS  Google Scholar 

  108. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94(9):3234–41.

    PubMed  CAS  Google Scholar 

  109. Sykes M, Eisenthal A, Sachs DH. Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component. J Immunol 1988;140(9):2903–11.

    PubMed  CAS  Google Scholar 

  110. Kawai T, Cosimi AB, Colvin RB, Powelson J, Eason J, Kozlowski T, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995;59(2):256–62.

    PubMed  CAS  Google Scholar 

  111. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343(11):750–8.

    Article  PubMed  CAS  Google Scholar 

  112. Schwartz RS. The new immunology--the end of immunosuppressive drug therapy? N Engl J Med 1999;340(22):1754–6.

    Article  PubMed  CAS  Google Scholar 

  113. Thomas E, D., Buckner CD, Rudolph RH, et al.Allogeneic marrow grafting for hematologic malignancy using HLA matched donor-recipient sibling pairs. 38 1971(267–287).

    CAS  Google Scholar 

  114. Santos GW, Sensenbrenner LL, Burke PJ, Colvin M, Owens AH, Jr., Bias WB, et al. Marrow transplanation in man following cyclophosphamide. Transplant Proc 1971;3(1):400–4.

    PubMed  CAS  Google Scholar 

  115. Yoshimura N, Kahan BD. Pharmacodynamic assessment of the in vivo cyclosporine effect on interleukin-2 production by lymphocytes in kidney transplant recipients. Transplantation 1985;40(6):661–6.

    Article  PubMed  CAS  Google Scholar 

  116. Prince HE, John JK. Cyclosporine inhibits the expression of receptors for interleukin 2 and transferrin on mitogen-activated human T lymphocytes. Immunol Invest 1986;15(5):463–72.

    Article  PubMed  CAS  Google Scholar 

  117. Bishop DK, Li W. Cyclosporin A and FK506 mediate differential effects on T cell activation in vivo. J Immunol 1992;148(4):1049–54.

    PubMed  CAS  Google Scholar 

  118. Eugui EM, Allison AC. Immunosuppressive activity of mycophenolate mofetil. Ann N Y Acad Sci 1993;685:309–29.

    Article  PubMed  CAS  Google Scholar 

  119. Shank B, Chu FC, Dinsmore R, Kapoor N, Kirkpatrick D, Teitelbaum H, et al. Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants. Int J Radiat Oncol Biol Phys 1983;9(11):1607–11.

    Article  PubMed  CAS  Google Scholar 

  120. Thomas ED, Clift RA, Hersman J. Marrow transplantation for acute non-lymphoblastic leukemia in first remission using fracionated or single-dose irradiation. Int J Radiat Oncol Biol Phys 1982;8:817-.

    Article  PubMed  CAS  Google Scholar 

  121. Santos GW, Sensenbrenner LL, Burke PJ, Mullins GM, Anderson PN, Tutschka PJ, et al. Allogeneic marrow grafts in man using cyclophosphamide. Transplant Proc 1974;6(4):345–8.

    PubMed  CAS  Google Scholar 

  122. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994;84(6):203–643.

    Google Scholar 

  123. Devergie A, Blaise D, Attal M, Tigaud JD, Jouet JP, Vernant JP, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfancytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 1995;85(8):2263–8.

    PubMed  CAS  Google Scholar 

  124. Blume KG, Forman SJ, O’Donnell MR, Doroshow JH, Krance RA, Nademanee AP, et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987;69(4):101–520.

    Google Scholar 

  125. Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant 1997;3(6):324–30.

    PubMed  CAS  Google Scholar 

  126. Horning SJ, Negrin RS, Chao JC, Long GD, Hoppe RT, Blume KG. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol 1994;12(12):2552–8.

    PubMed  CAS  Google Scholar 

  127. Weaver CH, Petersen FB, Appelbaum FR, Bensinger WI, Press O, Martin P, et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 1994;12(12):2559–66.

    PubMed  CAS  Google Scholar 

  128. Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S, et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987;70(3):869–72.

    PubMed  CAS  Google Scholar 

  129. Riddell S, Appelbaum FR, Buckner CD, Stewart P, Clift R, Sanders J, et al. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. J Clin Oncol 1988;6(4):576–82.

    PubMed  CAS  Google Scholar 

  130. Jillella AP, Doria R, Khan K, Zelterman D, Ahmad YH, Smith BR, et al. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Bone Marrow Transplant 1999;23(11):1095–100.

    Article  PubMed  CAS  Google Scholar 

  131. Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Hui TE, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999;94(4):1237–47.

    PubMed  CAS  Google Scholar 

  132. Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfanCytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d’Etudes de la Greffe de Moelle Osseuse. Blood 1992; 79(10):2578–82.

    PubMed  CAS  Google Scholar 

  133. Henner WD, Furlong EA, Flaherty MD, Shea TC, Peters WP. Measurement of busulfan in plasma by high-performance liquid chromatography. J Chromatogr 1987;416(2):426–32.

    PubMed  CAS  Google Scholar 

  134. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, et al. Pharmacokinetics of busulfan: correlation with venoocclusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989;25(1):55–61.

    Article  PubMed  CAS  Google Scholar 

  135. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993;20(4 Supp14):18–25;

    PubMed  CAS  Google Scholar 

  136. Andersson BS, Gajewski J, Donato M, Giralt S, Gian V, Wingard J, et al. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant 2000;26 Supp12:S35–8.

    Article  Google Scholar 

  137. Gale RP, Horowitz MM, Ash RC, Champlin RE, Goldman JM, Rimm AA, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994;120(8):646–52.

    PubMed  CAS  Google Scholar 

  138. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75(3):555–62.

    PubMed  CAS  Google Scholar 

  139. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLAidentical siblings as treatment of acute and chronic leukemia. Blood 1989;73(6):1720–8.

    PubMed  CAS  Google Scholar 

  140. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988;108(6):806–14.

    PubMed  CAS  Google Scholar 

  141. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991;78(8):2120–30.

    PubMed  CAS  Google Scholar 

  142. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76(12):2462–5.

    PubMed  CAS  Google Scholar 

  143. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994;330(2):100–6.

    Article  PubMed  CAS  Google Scholar 

  144. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86(5):2041–50.

    PubMed  CAS  Google Scholar 

  145. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995;86(11):4337–43.

    PubMed  CAS  Google Scholar 

  146. Collins RH, Jr., Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15(2):433–44.

    PubMed  Google Scholar 

  147. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996;87(3):1196–8.

    PubMed  CAS  Google Scholar 

  148. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. Lancet 1996;347(9004):800–1.

    Article  PubMed  CAS  Google Scholar 

  149. deMagalhaes-Silverman M, Donnenberg A, Hammert L, Lister J, Myers D, Simpson J, et al. Induction of graft-versus-leukemia effect in a patient with chronic lymphocytic leukemia. Bone Marrow Transplant 1997;20(2):175–7.

    Article  PubMed  CAS  Google Scholar 

  150. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997;157:125–40.

    Article  PubMed  CAS  Google Scholar 

  151. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999;93(7):2336–41.

    PubMed  CAS  Google Scholar 

  152. Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A 1999;96(15):8639–44.

    Article  PubMed  CAS  Google Scholar 

  153. Vogt MH, Goulmy E, Kloosterboer FM, Blokland E, de Paus RA, Willemze R, et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood 2000;96(9):3126–32.

    PubMed  CAS  Google Scholar 

  154. Blume KG, Forman SJ, Nademanee AP, O’Donnell MR, Snyder DS, Fahey JL, et al. Bone marrow transplantation for hematologic malignancies in patients aged 30 years or older. J Clin Oncol 1986;4(10):1489–92.

    PubMed  CAS  Google Scholar 

  155. Klingemann HG, Storb R, Fefer A, Deeg HJ, Appelbaum FR, Buckner CD, et al. Bone marrow transplantation in patients aged 45 years and older. Blood 1986;67(3):770–6.

    PubMed  CAS  Google Scholar 

  156. Ringden O, Horowitz MM, Gale RP, Biggs JC, Gajewski J, Rimm AA, et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. Jama 1993;270(1):57–60.

    Article  PubMed  CAS  Google Scholar 

  157. Epstein RB, Storb R, Ragde H, Thomas ED. Cytotoxic typing antisera for marrow grafting in littermate dogs. Transplantation 1968;6(1):45–58.

    Article  PubMed  CAS  Google Scholar 

  158. Storb R, Epstein RB, Rudolph RH, Thomas ED. The effect of prior transfusion on marrow grafts between histocompatible canine siblings. J Immunol 1970;105(3):627–33.

    PubMed  CAS  Google Scholar 

  159. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versusleukemia without myeloablative therapy. Blood 1997;89(12):4531–6.

    PubMed  CAS  Google Scholar 

  160. Giralt S, Cohen A, Mehra R, Gajewski J, Andersson B, Przepiorka Dea. Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation (ALLO-PCT) in poor candidates for conventional myeloablative conditioning. Blood 1997;90:417a.

    Google Scholar 

  161. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97(3):631–7.

    Article  PubMed  CAS  Google Scholar 

  162. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O’Brien S, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16(8):2817–24.

    PubMed  CAS  Google Scholar 

  163. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91(3):756–63.

    PubMed  CAS  Google Scholar 

  164. McSweeney PA, Wagner JL, Maloney DG, Radich H, Shizuru J, Bensinger WIea. Outpatient PBSC allografts using immunosuppression with low-dose TBI before and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant. Blood 1998;92(Suppl 1):519a.

    Google Scholar 

  165. McSweeney PA, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999;5(4):192–203.

    Article  PubMed  CAS  Google Scholar 

  166. Spitzer TR, McAfee SL, Sackstein R, Toh HC, Saidman S, Weymouth Dea. Induction of mixed chimerism and potent anti-tumor responses following non-myeloablative conditioning therapy and HLAmatched and mismatched donor bone marrow transplantation (BMT) for refractory hematologic malignancies (HM). Blood 1998;92(Suppl 11):519a.

    Google Scholar 

Download references

Authors
  1. Januario E. Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward D. Ball
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Blood and Marrow Transplantation Division, University of California, San Diego, USA

    Asad Bashey M.D., Ph.D.  & Edward D. Ball M.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Castro, J.E., Ball, E.D. (2002). Development of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). In: Bashey, A., Ball, E.D. (eds) Non-Myeloablative Allogeneic Transplantation. Cancer Treatment and Research, vol 110. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0919-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0919-6_1

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5304-1

  • Online ISBN: 978-1-4615-0919-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation